The estimated Net Worth of Daniel Karp is at least $93.1 Thousand dollars as of 2 July 2019. Mr. Karp owns over 196 units of Biogen stock worth over $93,058 and over the last few years he sold BIIB stock worth over $0. In addition, he makes $0 as Executive Vice President and Corporate Development at Biogen.
Mr. Karp BIIB stock SEC Form 4 insider trading
Daniel has made over 1 trades of the Biogen stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 196 units of BIIB stock worth $56,644 on 2 July 2019.
The largest trade he’s ever made was exercising 196 units of Biogen stock on 2 July 2019 worth over $56,644. On average, Daniel trades about 65 units every 0 days since 2018. As of 2 July 2019 he still owns at least 322 units of Biogen stock.
You can see the complete history of Mr. Karp stock trades at the bottom of the page.
Daniel Karp biography
Daniel Karp has served as an Executive Vice President, Corporate Development of Biogen Inc. since June 2018. Prior to joining Biogen, Mr. Karp held a number of positions of increasing responsibility at Pfizer, a biopharmaceutical company, including as Vice President, Worldwide Business Development and Head of Business Development for Worldwide Research and Development from May 2016 to June 2018, as Vice President, Worldwide Business Development and BD Lead for Pfizer Vaccines, Oncology and Consumer Healthcare from January 2014 to May 2016, as Senior Director, Worldwide Business Development from December 2010 to December 2013, as Director, Worldwide Business Development from January 2008 to December 2010, as Senior Manager, Worldwide Business Development from May 2007 to December 2007 and as Manager, U.S. Business Development from July 2006 to April 2007. Prior to that, Mr. Karp held roles in healthcare and life sciences strategy consulting.
How old is Daniel Karp?
Daniel Karp is 41, he’s been the Executive Vice President and Corporate Development of Biogen since 2018. There are 20 older and no younger executives at Biogen. The oldest executive at Biogen, Inc. is Lynn Schenk, 74, who is the Independent Director.
What’s Daniel Karp’s mailing address?
Daniel’s mailing address filed with the SEC is BIOGEN INC., 225 BINNEY ST., CAMBRIDGE, MA, 02142.
Insider trading at Biogen
Over the last 16 years, insiders at Biogen have traded over $156,919,925 worth of Biogen stock and bought 660,866 units worth $181,912,701 . The most active insider traders include Alexander J Denner, Stelios Papadopoulos, and George A Scangos. On average, Biogen executives and independent directors trade stock every 9 days with the average trade being worth of $3,890,229. The most recent stock trade was executed by Ginger Gregory on 1 August 2019, trading 179 units of BIIB stock currently worth $51,731.
What does Biogen do?
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
What does Biogen’s logo look like?
Complete history of Mr. Karp stock trades at Biogen
Biogen executives and stock owners
Biogen executives and other stock owners filed with the SEC include:
- Michel Vounatsos, Chief Executive Officer, Director
- Alfred Sandrock, Executive Vice President, Chief Medical Officer
- Michael Ehlers, Executive Vice President, Research and Development
- Susan Alexander, Executive Vice President, Chief Legal Officer and Secretary
- Jeffrey Capello, Chief Financial Officer, Executive Vice President
- Stelios Papadopoulos, Independent Chairman of the Board
- Robert Pangia, Independent Director
- Brian Posner, Independent Director
- Lynn Schenk, Independent Director
- Stephen Sherwin, Independent Director
- Alexander Denner, Independent Director
- Caroline Dorsa, Independent Director
- Eric Rowinsky, Independent Director
- Richard Mulligan, Independent Director
- Nancy Leaming, Independent Director
- Jesus Mantas, Director
- William Hawkins, Director
- John Chiminski, Director
- Robin Kramer, Chief Accounting Officer, Vice President
- Daniel Karp, Executive Vice President, Corporate Development
- Chirfi Guindo, Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation
- Ginger Gregory, Chief Human Resource Officer, Executive Vice President
- George A Scangos, Chief Executive Officer
- Adriana Karaboutis, EVP, Tech. and Bus. Solutions
- Gregory F Covino, VP, Chief Accounting Officer
- Paul Mc Kenzie, EVP Pharmaceutical Oper & Tech
- Paul J Clancy, CFO
- Kenneth Di Pietro, EVP Human Resources
- Adam Koppel, SVP, Chief Strategy Officer
- Jean Paul Kress, EVP Pres Int’l & Global Hd GTO
- Phillip A Sharp, Director
- Steven H Holtzman, EVP Corp Devel and Strategy
- John Cox, EVP Pharmaceutical Oper & Tech
- Spyridon Artavanis Tsakonas, SVP, Chief Scientific Officer
- William Young, Director
- Raymond Pawlicki, SVP, Chief Information Officer
- Stuart A Kingsley, EVP, Global Comm. Operations
- Douglas E Williams, EVP Research & Development
- Craig Eric Schneier, EVP, Human Resources
- Robert E. Gagnon, Chief Acct Officer VP & Contr
- Francesco Granata, EVP Global Commercial Operatio
- James C Mullen, CEO and President
- Michael F Mac Lean, SVP, Chief Accounting Officer
- Bruce Ross, Director
- Robert A Hamm, SVP, Immunology Business Unit
- Cecil B Pickett, President, R & D
- Marijn E Dekkers, Director
- Lawrence C Best, Director
- Faheem Hasnain, SVP, Oncology SBU
- Hans Peter Hasler, SVP, International
- Mark C Wiggins, EVP – Business Development
- Michael Lytton, EVP Corporate & Business Devel
- Alan Glassberg, Director
- John Michael Dunn, EVP – New Ventures
- Michael Gilman, EVP – Research
- Thomas J Bucknum, EVP. General Counsel, Sec.
- Nabil Hanna, EVP, Research
- William H Rastetter, Executive Chairman
- William R Rohn, Exec VP & COO
- Sylvie L Gregoire, EVP, Bus. Dev & Program Mgmt.
- Burt A Adelman, EVP, Development
- Alan Belzer, Director
- Michael Kowolenko, SVP, Pharm Ops & Technology
- Peter N Kellogg, Executive Vice President, CFO
- Mary L Good, Director
- Thomas F Keller, Director
- Connie Matsui, Sr V P, Planning& Resource Dev







